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Excision Repair
Cross-Complementing-1
for Small Cell Lung
Cancer
To the Editor:
We read the article by Rossi et
al.1 in the November issue of the Jour-
nal of Thoracic Oncology with great
interest. In the article, the authors
summarized six studies, including our
previous study,2 regarding the expres-
sion of excision repair cross-comple-
menting-1 (ERCC1) in small cell lung
cancer. Overall, the expression of
ERCC1 was not correlated with the
response to platinum-based chemo-
therapy; however, low expression of
ERCC1 was significantly associated
with good prognosis in patients with
limited disease (LD) in three studies.
Based on these data, they speculated
that ERCC1 expression is a prognostic
rather than a predictive marker of re-
sponse to platinum-based chemother-
apy only in patients with LD; how-
ever, they did not take account of the
influence of radiotherapy.
The proportion of patients who
received thoracic radiotherapy was re-
ported in two of the three studies, ex-
cluding the study by Rossi et al.,1 with
35 of 40 (87%) and 38 of 45 (84%)
patients with LD receiving thoracic ra-
diotherapy in the study by Lee et al.3 and
Ceppi et al.,4 respectively. Although the
precise mechanism remains to be eluci-
dated, previous in vitro studies have
shown that low ERCC1 expression is
associated with a high sensitivity to ra-
diation5; therefore, patients who re-
ceived thoracic radiotherapy were ex-
cluded from analysis in our study.2
To date, many studies have been
reported concerning the expression of
ERCC1 also in non-small cell lung can-
cer; however, the results are diverse,
there is no consensus, and it has not
been accepted for clinical use. The role
of ERCC1 is complex, and further stud-
ies are necessary for better understand-
ing of the function of ERCC1 in both
chemoresistance and radioresistance.
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In Response:
The point raised by Kim et al. on
the poorly known role of excision repair
cross-complementing-1 (ERCC1) ex-
pression as predictive marker of radio-
therapy effectiveness in small cell lung
cancer is quite appropriate.
We would like to point out that
48 patients in our series underwent
radiotherapy plus chemotherapy. How-
ever, ERCC1 expression in this sub-
group of patients did not significantly
correlate with clinical objective re-
sponse, even considering the different
disease stage (33 with limited disease
and 14 with extensive disease).
As in the overall population,
ERCC1 was significantly associated
with overall and disease-free survival
but not with response to therapy. Al-
though of limited value, these latter
observations do not seem to confirm a
role of ERCC1 expression with sensi-
tivity to radiation in small cell lung
cancer.
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